Menu
Recruiting NCT06322433

Follow up of High Myopic Eyes

Observational Pathologic Myopia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: no drugs used for this study.
Who it may be relevant to
Registry conditions: Pathologic Myopia. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Italy
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Long Term Follow-up of Eyes With High Myopia

Overview

In this non-interventional retrospective and prospective observational study, the long-term evolution of clinical and iconographic characteristics of patients with pathological myopia will be considered Changes of some specific clinical, tomographic and angiographic variables evaluated on the baseline and after a minimum of 5 years follow-up will be studied.

Interventions

  • Diagnostic test no drugs used for this study
    tomographic, angiographic and clinical follow up

Primary outcome measures

  • Proportion of subjects with neovascularization at follow-up visit [Time frame: at 5 years of follow up]

Eligibility criteria

Inclusion criteria

\- high myopia

Exclusion criteria

  • acute ischemic optic neuropathy
  • macular and peripapillary atrophy
  • other forms of maculopathy

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Italy · 1 center
  • Istituto Auxologico Italiano IRCCS — Milan

Identifiers

NCT: NCT06322433 · 37C301

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗